Four IPOs in one night after Dicerna triples on 1st day
This article was originally published in Scrip
Three biotechnology companies went public in a single night on 30 January when Ultragenyx, Trevena and Cara Therapeutics launched initial public offerings and Intra-Cellular Therapies priced an additional IPO to move its stock to the Nasdaq index.
You may also be interested in...
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.